Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure

Arthritis Research and Therapy

Volumn 8, Issue 2, 2006, Pages

  Kapral, Theresa ^a   Stamm, Tanja ^a   Machold, Klaus P ^a   Montag, Karin ^b   Smolen, Josef S ^a,b   Aletaha, Daniel ^a,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b GENERAL HOSPITAL LINZ   (Austria)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; METHOTREXATE;

ACUTE PHASE RESPONSE; AGED; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; MALE; MEDICAL RECORD; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RETREATMENT; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ACUTE-PHASE REACTION; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MEDICAL RECORDS; METHOTREXATE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETREATMENT; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 70350525192     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1902     Document Type: Article

References (38)

1. Graudal NA, Jurik AG, de Carvalho A, Graudal HK: Radiographic progression in rheumatoid arthritis: A long-term prospective study of 109 patients. Arthritis Rheum 1998, 41:1470-1480.
2. Eberhardt KB, Fex E: Functional impairment and disability in early rheumatoid arthritis: Development over 5 years. J Rheumatol 1995, 22:1037-1042.
3. Spector TD, Scott DL: What happens to patients with rheumatoid arthritis? The long-term outcome of treatment. Clin Rheumatol 1988, 7:315-330.
4. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Haga M, Kleinheksel SM, Cathey MA: The mortality of rheumatoid arthritis. Arthritis Rheum 1994, 37:481-494.
5. Emery P: Early rheumatTid arthritis: therapeutic strategies. Scand J Rheumatol Suppl 1994, 100:3-7.
6. Fries JF: Effectiveness and toxicity considerations in outcome directed therapy in rheumatoid arthritis. J Rheumatol Suppl 1996, 44:102-106.
7. Hurst S, Kallan MJ, Wolfe FJ, Fries JF, Albert DA: Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects. J Rheumatol 2002, 29:1639-1645.
8. Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, Wolfe T: Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: Updating a 1983 review. Rheumatology (Oxford) 2002, 41:1346-1356.
9. Aletaha D, Smolen JS: The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 2002, 41:1367-1374.
10. Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, von Hinueber U, Gromnica-Ihle E, Wassenberg S, Antoni C, et al.: Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005, 64 1274-1279.
11. Aletaha D, Smolen JS: Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 2002, 29:1631-1638.
12. Felson DT, Anderson JJ, Meenan RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990, 33:1449-1461.
13. Pincus T, Marcum SB, Callahan LF: Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992, 19:1885-1894.
14. Pincus T, Marcum SB, Callahan LF, Adams RF, Barber J, Barth WF, Gordon GV, Huston JW, Polk JR, Whelton JC, et al.: Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: I. Nonsteroidal antiinflammatory drugs. J Rheumatol 1992, 19:1874-1884.
15. Wolfe F, Hawley DJ, Cathey MA: Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990, 17 994-1002.
16. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 2004, 364:263-269.
17. Smolen JS, Sokka T, Pincus T, Breedveld FC: A proposed treatment algorithm for rheumatoid arthritis: Aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003, 21 (5 Suppl 31):S209-S210.
18. Weinblatt ME: RheumatoidWarthritis in 2003: where are we now with treatment? Ann Rheum Dis 2003, 64 Suppl 2:iI94-ii96.
19. Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL: Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003:iI30-ii33.
20. Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS: Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum 2003, 48 3308-3319.
21. Weaver AL: The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2004, 43 Suppl 3 iii17-iii23.
22. Dougados M, Emery P, Lemmel EM, Zerbini CA, Brin S, van Riel P: When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? Ann Rheum Dis 2005, 64:44-51.
23. Smolen JS, Aletaha D, Keystone E: Superior efficacy of combination therapy: Fact or fiction? Arthritis Rheum 2005, 52 2975-2983.
24. Aletaha D, Smolen JS: Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: Clinical evaluation and cost analysis. Arthritis Rheum 2002, 47 181-188.
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healay LA, Kapan SR, Liang MH, Luthra HS, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
26. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985, 312:818-822.
27. Aletaha D, Kapral T, Smolen JS: Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 2003, 62:482-486.
28. Grove ML, Hassell AB, Hay EM, Shadforth MF: Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM 2001, 94:309-319.
29. McKendry RJ, Dale P: Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993, 20:1850-1856.
30. Menkes CJ: Effects of disease-modifying anti-rheumatic drugs, steroids and non-steroidal anti-inflammatory drugs on acutephase proteins in rheumatoid arthritis. Br J Rheumatol 1993, 32 Suppl 3:14-18.
31. Otterness IG: The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum 1994, 24 91-104.
32. Wolfe F, Michaud K: The clinical and research significance of the erythrocyte sedimentation rate. J Rheumatol 1994, 21 1227-1237.
33. Wolfe F: Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997, 24:1477-1485.
34. Aletaha D, Smolen JS: Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeutics. Curr Rheumatol Rep 2003, 5:409-412.
35. Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V: Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: A randomized, controlled trial. Arthritis Rheum 2004, 50:364-371.
36. Khanna D, Park GS, Paulus HE, Simpson KM, Elashoff D, Cohen SB, Emery P, Dorrier C, Furst DE: Reduction of the efficacy of methotrexate by the use of folic acid: Post hoc analysis from two randomized controlled studies. Arthritis Rheum 2005, 52:3030-3038.
37. Rau R: Bioavailability of higher dose MTX comparing oral and subcutaneous administration in patients with RA. J Rheumatol 2005, 32:1412-1413.
38. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS: Methotrexate as the 'anchor drug' for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003, 25(5 Suppl 31):S179-S185.